Chemotherapy Market, Insights, Revenue Forecast, Competitive Landscape, Growth Factors, and Trends : Information by Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors and Antitumor Antibiotic), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), Route of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and End-User (Specialty Centers and Hospitals Clinics)
The Global Chemotherapy Market is estimated to be valued at USD 56,491.59 Million by 2024 and is expected to register a CAGR of 11.50% during the forecast period.
The alkylating agents segment dominated the global chemotherapy market, by drug class, and is projected to reach USD 20,360.32 Million by 2024 and projected to be the fastest-growing segment during the forecast period.
Americas dominated the market, accounting for the largest share of the market in 2018, and the regional market is expected to register a CAGR of 10.88% during the review period. The European market was the second largest in 2018. The market is projected to reach USD 18,292.73 Million by the end of 2024, with Germany being the leading market.
The Global Chemotherapy Market has been segmented on the basis of drug class, indication, route of administration, end user, and region. On the basis of drug class, the market has been divided into alkylating agents, antimetabolites, mitotic inhibitors, antitumor antibiotic, and topoisomerase inhibitors. The alkylating agents segment held the majority market share in 2018 and anticipated to be the fastest growing, followed by the mitotic inhibitors segment.
On the basis of indication, the market has been divided into lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach cancer, leukemia, lymphoma, and ovarian cancer. The lung cancer segment accounted for the larger market share in 2018. However, the breast cancer segment is expected to exhibit higher CAGR during the forecast period.
On the basis of route of administration, the market has been divided into intravenous, oral, subcutaneous, intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/intrathecal. The intravenous segment accounted for the larger market share in 2018. However, the oral segment is expected to exhibit higher CAGR during the forecast period.
On the basis of end user, the market has been divided into specialty centers, hospitals clinics, and others. The specialty centers segment accounted for the larger market share in 2018 and expected to exhibit higher CAGR during the forecast period.
Market Research Future (MRFR) recognizes Johnson Johnson Services Inc (US), GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), Merck Co. Inc. (US), Sanofi S.A. (France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US) as the key players in the global chemotherapy market.
Geographically, the global chemotherapy market has been segmented into the Americas, Europe, Asia-Pacific, and Middle East Africa. As per MRFR analysis, the Americas was the largest market for chemotherapy in 2018 and is expected to remain dominant during the review period. Europe accounted for a significant market share and is projected to be the second-largest market during the forecast period. The increasing prevalence of cancer is a major driving factor for the growth of the chemotherapy market in Europe. Germany accounted for the largest market share of 27.07% in 2018 and projected to register a CAGR of 11.45% during the forecast period.
Key Findings of the Study:
- The Global Chemotherapy Market is projected tao reach over USD 56,491.59 million by 2024 at an 50% CAGR during the review period of 2019 to 2024.
- Americas accounted for the largest market share with the US being the major contributor to the growth of the market.
- The breast cancer indication segment is projected to register the highest CAGR of 11.94% during the forecast period.
- Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies.
- Chemotherapy-induced myelosuppression is the most common dose-limiting and potentially fatal complication of cancer treatment.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]